ArticleNature communications2022
Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed.
- Antibodies targeting phage fiber and nozzle proteins impair Acinetobacter baumannii phage therapy by blocking infection and promoting immune clearance.PLoS biology · 2026Article
- Mechanisms of Resistance, Insights From Case Reports, and Future Prospects in Mycobacteriophage Therapy.Journal of the Royal Society of New Zealand · 2026Review
- Bacteriophage therapy for multidrug-resistant bacterial infections: recent advances, clinical evidence, and translational challenges.Archives of microbiology · 2026Review
- CutaneousMicroorganisms · 2026Article
- Immune Responses to Phage Therapy in Humans: A Review.The Journal of infectious diseases · 2026Review
- Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.Molecular biotechnology · 2026Review
- Smooth-to-rough morphotype switching, a mechanism of phage resistance inProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Exploring the molecular properties and bactericidal potential of Lysin B from mycobacteriophage WXIN.BMC microbiology · 2026Article
- The Role of Genomics in Advancing and Standardising Bacteriophage Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Genomic profile and infection dynamics of Kashi_RDG1 (KRDG1), a novel cluster K1 mycobacteriophage infecting mycobacterial hosts.Frontiers in microbiology · 2026Article
- Clinical and Translational Perspectives on Bacteriophage Therapy for Nontuberculous Mycobacterial Diseases.Journal of microbiology and biotechnology · 2025Review
- Phage therapy of perinephric abscess in kidney transplantation recipients caused by drug-resistantmLife · 2025Article
- Exploration of the feasibility of clinical application of phage treatment for multidrug-resistantEmerging microbes & infections · 2025Article
- Advances in combating antimicrobial resistance in MRSA: a comprehensive review on nanotechnology and phage therapy.Antonie van Leeuwenhoek · 2025Review
- Development of an inhalable dry powder of mycobacteriophage D29 using thin-film freeze-drying.International journal of pharmaceutics · 2025Article
- Phage and enzyme therapies in wound infections: From lab to bedside.Chinese medical journal · 2025Review
- Temporal dynamics, microdiversity, and ecological functions of viral communities during cyanobacterial blooms in Lake Taihu.NPJ biofilms and microbiomes · 2025Article
- Cryo-EM and cryo-ET reveal the molecular architecture and host interactions of mycobacteriophage Douge.Cell reports · 2025Article
- Article
- Reconstructing the Antibiotic Pipeline: Natural Alternatives to Antibacterial Agents.Biomolecules · 2025Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Mycobacterium chelonae is a rare cause of chronic disseminated cutaneous infections in immunocompromised patients. Multidrug-resistant M. chelonae infections present a challenge for treatment, and prolonged antimicrobial courses lead to significant toxicities and further antimicrobial resistance. We report a case of refractory cutaneous disseminated M. chelonae infection in a patient with seronegative arthritis on immunotherapy with tofacitinib that was treated with combination antimicrobial, surgical, and single bacteriophage therapy with excellent clinical response. The patient developed neutralizing antibodies against the bacteriophage but continues to have stable improvement of disease with negative biopsies and no evidence of bacterial resistance to the phage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.